Swan Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Swan Capital’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$4	–	532
2025 Q2	$4	Buy	+1	New	+$4	﹤0.01%	478

Other funds holding OLMA

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Swan Capital's OLMA Position: Q3 2025 in Review

Swan Capital sold out of Olema Pharmaceuticals (OLMA) in Q3 2025, closing a stake of 1 share — an estimated $4 sold.

Swan Capital first reported a position in OLMA in Q2 2025 and held it in 1 quarter. The position peaked at $4 in Q2 2025. 126 funds tracked by Wall St. Rank hold OLMA as of Q3 2025.

Swan Capital reported no remaining Olema Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Swan Capital sold 1 Olema Pharmaceuticals share in Q3 2025, an estimated $4.
Swan Capital first reported a position in Olema Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Swan Capital's Olema Pharmaceuticals position peaked at $4 in Q2 2025.
126 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q3 2025.

Based on Swan Capital's 13F filing for Q3 2025, filed 14 Nov 2025.